Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. on December 26, 2018, covering events occurring on December 21, 2018. The filing addresses the departure of a senior executive and the subsequent establishment of a consulting arrangement.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the resignation of Nitya Ray, who served as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain. The departure was amicable, with no disagreement regarding company operations, policies, or practices.
Outlook, Management Commentary, and Risks
Following his resignation, Dr. Ray entered into a three-month consulting agreement with the Company. Key terms include:
- Consulting fee rate: $250 per hour.
- Maximum hours: Up to 20 hours per week.
- Extension option: The Company may extend the arrangement by an additional three months.
A copy of the Consulting Agreement is scheduled to be included as an exhibit to the Company's Form 10-K for the year ending December 31, 2018. No other risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the terms of the Consulting Agreement in the upcoming Form 10-K exhibit.
- Confirm the Company's plan for filling the Executive Vice-President role or redistributing the responsibilities of Product Development, Manufacturing, and Supply Chain.
- Review the Form 10-K for the full year 2018 to assess the financial impact of this personnel change.